Targeting KRAS mutant cancers: from druggable therapy to drug resistance
C Zhu, X Guan, X Zhang, X Luan, Z Song, X Cheng… - Molecular cancer, 2022 - Springer
Abstract Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) is the most frequently
mutated oncogene, occurring in a variety of tumor types. Targeting KRAS mutations with …
mutated oncogene, occurring in a variety of tumor types. Targeting KRAS mutations with …
Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer
L Buscail, B Bournet, P Cordelier - Nature reviews Gastroenterology & …, 2020 - nature.com
Pancreatic ductal adenocarcinoma (PDAC) is predicted to be the second most common
cause of death within the next 10 years. The prognosis for this disease is poor despite …
cause of death within the next 10 years. The prognosis for this disease is poor despite …
Role of PI3K/AKT pathway in cancer: the framework of malignant behavior
N Jiang, Q Dai, X Su, J Fu, X Feng, J Peng - Molecular biology reports, 2020 - Springer
Given that the PI3K/AKT pathway has manifested its compelling influence on multiple
cellular process, we further review the roles of hyperactivation of PI3K/AKT pathway in …
cellular process, we further review the roles of hyperactivation of PI3K/AKT pathway in …
Mutations in key driver genes of pancreatic cancer: molecularly targeted therapies and other clinical implications
H Hu, Z Ye, Y Qin, X Xu, X Yu, Q Zhuo… - Acta Pharmacologica …, 2021 - nature.com
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers, with a minimal
difference between its incidence rate and mortality rate. Advances in oncology over the past …
difference between its incidence rate and mortality rate. Advances in oncology over the past …
MicroRNA in pancreatic cancer
K Yonemori, H Kurahara, K Maemura… - Journal of human …, 2017 - nature.com
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies. Patients
with PDAC are often asymptomatic, and many have lymph node and distant metastases as …
with PDAC are often asymptomatic, and many have lymph node and distant metastases as …
A prospective strategy leveraging nanomedicine for cancer therapy: pouring ferroptosis on apoptosis
As a fundamental process of the programmed cell death, apoptosis has endowed
nanomedicine broad horizons to treat tumor. However, apoptosis-resistance elicited by …
nanomedicine broad horizons to treat tumor. However, apoptosis-resistance elicited by …
Pancreatic cancer in chronic pancreatitis: pathogenesis and diagnostic approach
G Le Cosquer, C Maulat, B Bournet, P Cordelier… - Cancers, 2023 - mdpi.com
Simple Summary Chronic alcoholic pancreatitis displays a cumulative risk of pancreatic
cancer estimated at 4% after 15 to 20 years, this risk being higher for hereditary pancreatitis …
cancer estimated at 4% after 15 to 20 years, this risk being higher for hereditary pancreatitis …
RAS in pancreatic cancer
S Lanfredini, A Thapa, E O'Neill - Biochemical Society …, 2019 - portlandpress.com
The pancreas is a gland composed mainly by endocrine and exocrine cells, giving rise to
three main tumour types. Pancreatic neuroendocrine tumour or PNET arise from the …
three main tumour types. Pancreatic neuroendocrine tumour or PNET arise from the …
A quarter century of EUS-FNA: Progress, milestones, and future directions
Tissue acquisition using EUS has considerably evolved since the first EUS-FNA was
reported 25 years ago. Its introduction was an important breakthrough in the endoscopic …
reported 25 years ago. Its introduction was an important breakthrough in the endoscopic …
Targeting KRAS in solid tumors: current challenges and future opportunities of novel KRAS inhibitors
Activating mutations in RAS family proteins are found in~ 25% of all human cancers.
Different solid tumors are correlated with mutations in certain isoforms of RAS, with Kirsten …
Different solid tumors are correlated with mutations in certain isoforms of RAS, with Kirsten …